Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : Chilean study shows variations in success of COVID-19 vaccines

08/03/2021 | 05:57pm EDT

SANTIAGO, Aug 3 (Reuters) - Sinovac's COVID-19 vaccine was 58.5% effective in preventing symptomatic illness among millions of Chileans who received it between February and July, the Chilean health authorities said on Tuesday, while Pfizer's COVID-19 shot was 87.7% effective and AstraZeneca's was 68.7% effective.

The data came in the latest "real world" data published by the Chilean authorities into the effectiveness among its population of a raft of COVID-19 vaccines.

Chile began one of the world's fastest inoculation campaigns against COVID-19 in December, having now fully vaccinated more than 60% of its population, predominantly with Sinovac's CoronaVac.

That vaccine was 86% effective in preventing hospitalization, 89.7% effective in preventing admission to intensive care units and 86% effective in preventing deaths within the population between February and July, health official Dr Rafael Araos said in a press conference on Tuesday.

In April, the same study found that CoronaVac was 67% effective in preventing symptomatic illness, 85% effective in preventing hospitalizations and 80% effective in preventing deaths, suggesting its capacity to prevent the more serious impacts of the virus has strengthened, while its capacity to stop symptomatic illness diminished.

Araos said a reduction in protection from vaccines was inevitable over time, particularly with the arrival and growing prevalence of more virulent strains such as the Delta variant.

"If Delta becomes more prevalent and the vaccine has a weaker response, we could observe a faster fall (in effectiveness)," he said, adding his voice to calls for a third, booster dose to be issued.

The government also published data on the effectiveness of other vaccines administered in Chile, made by Pfizer BioNTech and AstraZeneca.

Pfizer's vaccine was 87.7% effective in preventing symptomatic COVID-19 in the same period, 98% effective in preventing intensive care admission and 100% effective in preventing death, Araos said.

AstraZeneca's was 68.7% effective in preventing symptomatic COVID-19 in the same period, 98% effective in preventing intensive care admissions and 100% effective in preventing death, Araos said.

Chile's study examined the vaccines' effectiveness among different cohorts of people who either received two doses of the specified vaccine, partial doses of the vaccine or no vaccine at all.

The CoronaVac part of the study examined a group of 8.6 million people, the Pfizer BioNTech part studied a group of 4.5 million people and the AstraZeneca part looked at a group of 2.3 million people. (Reporting by Aislinn Laing and Fabian Cambero Editing by Chris Reese and Marguerita Choy)

ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -1.07% 8617 Delayed Quote.17.65%
SINOVAC BIOTECH LTD. -0.31% 6.47 Delayed Quote.0.00%
All news about ASTRAZENECA PLC
04:23pMODERNA : Canada paused COVID-19 vaccine deliveries as supply far exceeds demand
09:45aASTRAZENECA : Anger, confusion spread over UK's new COVID travel rules
07:20aPFIZER : COVID-19 Vaccine Elicits Strong Immune Response As Second Dose, Thailand Study Sa..
04:32aSINOVAC BIOTECH : Thailand delays plan to re-open cities to tourists until November
04:27aIndia's Serum Institute to invest $68 mln in UK vaccine maker Oxford Biomedica
04:03aASTRAZENECA : MEDIA-UK govt approves Covishield as qualified vaccine for travel - Mint
02:25aOXFORD BIOMEDICA : Swings to H1 Profit on Revenue from COVID-19 Vaccine Manufacturing
01:57aASTRAZENECA : India likely to allow smaller gap between AstraZeneca COVID vaccine doses so..
09/21Shangula Rages Against West's Vaccine Nationalism
09/21ASTRAZENECA : India calls new UK COVID-19 vaccine rules 'discriminatory'
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 401 M - -
Net income 2021 5 006 M - -
Net Debt 2021 24 250 M - -
P/E ratio 2021 32,8x
Yield 2021 2,40%
Capitalization 182 B 182 B -
EV / Sales 2021 5,82x
EV / Sales 2022 4,72x
Nbr of Employees 76 100
Free-Float 96,3%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 27
Last Close Price 117,33 $
Average target price 136,24 $
Spread / Average Target 16,1%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC17.65%184 103
JOHNSON & JOHNSON4.16%433 122
ROCHE HOLDING AG9.82%321 584
PFIZER, INC.20.08%246 246
NOVO NORDISK A/S52.07%234 070